ADVIKLA.BO · BSE
ADVIK LABORATORIES LTD.
₹2.08
+4.52% (+₹0.09)
Prev. close
₹1.99
Volume
1,450
As of
15 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About ADVIK LABORATORIES LTD.
MPS Pharmaa Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers generic products, including antibacterials, antiallergics, antifungals, anthelminthics, antihypertensives, antimalarials, antituberculosis, corticosteroids, erectile dysfunction, gastrointestinal agents, sedatives, and others, as well as analgesic, antipyretic, and anti-inflammatory products. It also offers ethical products, such as Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin, and Chewfe-C. In addition, the company exports its products to East Asia, Southeast Asia, the Middle East, South America, and Africa. The company was formerly known as Advik Laboratories Limited and changed its name to MPS Pharmaa Limited in December 2022. MPS Pharmaa Limited was incorporated in 1994 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Peeyush Kumar Aggarwal
Headquarters
New Delhi
Employees
18
Website
mpspharmaa.comExchange
View on BSE ↗Key stats
Market cap
₹3.98 Cr
EPS (TTM)
₹-0.53
Beta (1Y · daily vs NIFTY 50)
-0.04
Beta (5Y · monthly vs NIFTY 50)
0.11
Shares float
61.75 L
EPS · quarter ended Jun 2026
₹-0.12
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2026 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2026. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹19.50 L | ₹29.10 L | ₹2.30 L | ₹9.40 L | ₹4.80 L | ₹3.60 L | |
| EBITDA | ₹-3.94 Cr | ₹-41.83 L | ₹-92.47 L | ₹-70.50 L | ₹-71.67 L | ₹-91.04 L |
| ₹-4.42 Cr | ₹-14.20 L | ₹-1.05 Cr | ₹-83.10 L | ₹-89.80 L | ₹-1.02 Cr | |
| Diluted EPS | ₹-2.31 | ₹-0.07 | ₹-0.55 | ₹-0.43 | ₹-0.47 | ₹-0.53 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹10.19 Cr | ₹9.94 Cr | ₹9.33 Cr | ₹8.48 Cr | |
| — | — | ₹6.76 Cr | ₹7.27 Cr | ₹7.46 Cr | ₹7.52 Cr | |
| Stockholders' equity | — | — | ₹2.79 Cr | ₹1.97 Cr | ₹1.08 Cr | ₹6.85 L |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-86.55 L | ₹-63.32 L | ₹-56.99 L | ₹-58.98 L | |
| Investing cash flow | — | — | ₹-9.73 L | ₹12.33 L | ₹38.34 L | ₹52.33 L |
| Financing cash flow | — | — | ₹95.64 L | ₹50.84 L | ₹18.33 L | ₹6.53 L |
| Capital expenditure | — | ₹-1.13 L | ₹-11.73 L | ₹-1.69 L | ₹-39,504 | — |
| End cash position | — | — | ₹72,584 | ₹57,703 | ₹24,898 | ₹13,441 |
Operating cash flow, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| ADVIK LABORATORIES LTD. | ₹3.98 Cr | ₹2.08 | — | 58.01 | -1488.5% | 109.80 | — | +9.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 27
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.